| Revenue growth | ₹540cr consolidated revenue; CRDMO segment grew 60% YoY. |
|---|---|
| Margins | EBITDA margins steady at 38%; PAT margins at 24%. |
| Demand visibility | Strong visibility for commercialized molecules and emerging modalities like ADCs. |
| Management confidence | Balanced and optimistic, emphasizing technology edge and long-term partnerships. |
Growth
Consolidated revenue reached ₹540cr, driven by a 60% surge in the CRDMO segment. Growth is primarily volume-led across commercial products.
Outlook
Investing ₹150cr to finish Units 2 and 3; Unit 4 planning underway. Target 22% historical growth rate for full year.
Risks
Business model lumpiness makes quarterly performance inconsistent. Potential U.S. tariff shifts and client concentration in late-stage molecules remain key bear-case triggers.
Earnings Call filed with NSE, NSE: ANTHEM. Summary written with AI assistance from the document.
Anthem Biosciences Ltd: key numbers
- Share price
- ₹873.60
- Market cap
- ₹49,201 Cr
- Revenue (annual)
- ₹2,124 Cr
- Net profit (annual)
- ₹591.8 Cr
- P/E (TTM)
- 85.4×Sector 50.4×
- Promoter holding
- 71.42%-3.26% QoQ
- FII holding
- 2.57%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Anthem Biosciences Ltd
All →Anthem Biosciences Other Announcement
Designated Person Viridity Tone LLP sold shares of Anthem Biosciences Ltd worth ₹82.67 Crore via market sale.
- Value
- ₹82.67 Cr
Anthem Biosciences Legal & Regulatory
Anthem Biosciences Ltd announced the settlement of an upside sharing amount of ₹127.68 Crore related to a prior divestment, following shareholder approval.
- Value
- ₹127.7 Cr
Anthem Biosciences Earnings Call Transcript: Key Takeaways
Revenue fell 25% YoY due to deferred deliveries, though management claims a record order book will drive second-half recovery. While EBITDA margins remain high at 39.6%, the quarter reflects high lumpiness in the CRDMO business.
Anthem Biosciences Investor Presentation: Key Takeaways
Anthem reported Q1FY27 revenue of ₹4,182 Mn with a 39.6% EBITDA margin. Results reflect timing shifts in deliveries, though management reports strong underlying demand and year-on-year margin improvement.
Anthem Biosciences Q1 FY27 Results: Net Profit ₹119.9 Cr, Down 11.7% YoY
Anthem Biosciences Ltd reported revenue from operations of ₹418.2 Cr (-22.6% YoY) and net profit of ₹119.9 Cr (-11.7% YoY) for Q1 FY27.
- Key figure
- Net profit ₹119.9 Cr · -11.7% YoY
Anthem Biosciences Earnings Call: Key Takeaways
Anthem Biosciences delivered record Q4 performance with FY26 revenue of ₹2,280cr and 43.4% EBITDA margins, driven by CRDMO strength.